We are witnessing an explosion of new information related to the intersecting health problems of obesity and cardiovascular disease. A flurry of cardiovascular outcomes trials have demonstrated a remarkable, yet poorly understood, cardioprotective benefit of diabetes and obesity drugs. In parallel, recent breakthrough technologies and experimental approaches allow deep real-time interrogation of systemic, organ, and cellular metabolism. This symposium is designed to address a series of topics relevant to cardiometabolism in health and disease including:

1) the metabolic basis for heart and vascular health and disease;

2) organ-organ crosstalk relevant to the synergism between obesity, insulin resistance, and cardiovascular disease;

3) the mechanisms whereby new drugs such as SGLT2 inhibitors and GLP-1r agonists reduce cardiovascular events;

4) the impact of environmental factors such as feeding and diurnal behavior on cardiovascular health and disease.

Participants with expertise across an array of disciplines and themes including cellular and organismal metabolism, heart and vascular biology/physiology/disease, clinical and data science, clinical trial design, and new drug seekers will drive cross-disciplinary insights and breakthroughs. The conference will bring together basic, translational and clinical scientists in academia with industry partners engaged in the development and assessment of new treatments for the worldwide health problem of cardiometabolic diseases.

Additionally, this conference will be held jointly with the Keystone Symposium on “Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects,” to enable better understanding of the intersection of these diseases, and their treatments, accelerating clinical impacts across both fields.

In the video below, Dr. Daniel Kelly from the University of Pennsylvania Perelman School of Medicine, talks about what to expect at this meeting:

And, check out the speaker highlights: